DEXAMETHASONE Multidose and Single dose Preservative Free (Ophthalmology – Ocular Inflammations)

DEXAMETHASONE Multidose and Single dose Preservative Free (Ophthalmology – Ocular Inflammations)
Product Description

Dexamethasone is a long-acting synthetic adrenocorticoid with intense anti-inflammatory activity Thanks to its properties, dexamethasone is useful in the management of steroid-responsive inflammatory conditions such as uveitis, allergic conjunctivitis, iritis, or cyclitis; symptomatic treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

- Presentations: Multidose 5ml Novelia bottle, 20 or 30x 0.5ml Single Doses
- Class: Drug
Dossier Ready for registration

NTC S.r.l.

  • IT
  • 2015
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)

NTC S.r.l.

  • IT
  • 2015
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)

More Products from NTC S.r.l. (29)

NTC S.r.l. resources (9)

  • News NTC expands into pediatric allergology

    NTC Srl, R&D driven pharmaceutical companywith headquarters in Italy focused in ophthalmology, announces results from apolycentric study on Lertal®, a multicomponent nutraceutical, as add-on treatmentin children with allergic rhinoconjunctivitis (AR).
  • Brochure Therapeutical areas - brochure

    Advanced scientific research and technology drive our efforts to innovate care practices.
    Our range of products builds from our historical vocation for innovation aimed at improving the experience of patients and healthcare practices.
    An innovation aimed at discovering specific therapeutic gestures: simple and intuitive,  sustainable, and technically advanced for empowering the patient.
    Our research aims to put pioneering new products within the reach of everyone and to optimize the
    performance of our products by analyzing the daily needs and habits of people undergoing treatment.
    We research, develop and produce innovative drugs, medical devices and food supplements.
    We market our products worldwide through licensing, distribution, marketing, and commercial deals with partner companies.
    Our core therapeutic areas are: Ophthalmology, Gastro-Metabolism, Pediatrics and Gynacology.

  • News NTC news: Post-cataract surgery

    Last June, in Milan, NTC held a very important Investigators’ Meeting of two pivotal registration studies for a novel drug indicated in post cataract surgery: over 50 centers were involved in such large clinical effort and attended the event.
  • Brochure Value Report 2022

    We focus on Novelty, Technology and we Care of our partners, customers, patients and of our people.

    The following information is intended for healthcare professionals only.

  • Brochure Value Report 2021

    In NTC, we research, develop and produce innovative drugs, medical devices and food supplements.
    We market our products worldwide through licensing, distribution, marketing, and
    commercial deals with partner companies.
    In 2020, NTC consolidated its leadership in its fields of specialization by expanding its
    partnership network into Europe and Asia.
    Read more!
  • Brochure VALUE REPORT 2020

    As a global player in the area of B2B, NTC is present in almost 100 countries and workwith around 200 partner companies. In addition, it carries out direct commercial activities (B2C) in the field of Ophthalmology in Italy and Spain.Dedicated to creating sustainable value, NTC has integrated social and environmentalconsiderations into its business operations and into its dealings with stakeholders. As partof its commitment to Corporate Social Responsibility, NTC has embedded internationalguidelines and procedures in its processes and practices.